Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdams criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97)
Body composition: Some studies have reported slight reductions in fat mass, though results remain inconsistent across different populations
Stability: Store at -20C and avoid repeated freezing and thawing
Furthermore, disruption of adherens junctions, including E-cadherin and -catenin, rapidly decreases gap junction plaques, leading to reduced Cx32 levels
